Antigen News and Research

RSS

Interval of time to biochemical failure could be used as surrogate endpoint for prostate cancer

An analysis of the NRG Oncology clinical trial NRG-RTOG 9202 showed that the interval of time to biochemical failure, or the time it takes for previously treated cancer to return as indicated by prostate specific antigen rise, could be used as a surrogate endpoint for locally advanced prostate cancer.

21 Dec 2018

FDA supports C-Path's Type 1 Diabetes Consortium to pursue biomarker qualification

Critical Path Institute (C-Path) announced today that its Type 1 Diabetes (T1D) Consortium has received a positive response to its Letter of Intent (LOI) from the U.S. Food and Drug Administration (FDA) detailing the FDA's decision to accept the consortium's Biomarker Initiative project into the Center for Drug Evaluation and Research (CDER) Biomarker Qualification Program (BQP).

19 Dec 2018

Black men diagnosed with low-grade prostate cancer have higher risk of death, study shows

Black men diagnosed with prostate cancer classified as low risk may actually have a more-aggressive form of the disease that is more likely to be fatal than in nonblack men placed in the same prognostic category, a new study suggests.

18 Dec 2018

Surgical treatment unnecessary for many prostate cancer patients

Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian men with prostate cancer for 29 years. The results are now published in The New England Journal of Medicine.

12 Dec 2018

Whole-body imaging PET/MRI offers information to guide treatment options for prostate cancer

New research on prostate cancer staging shows that PSMA-targeted PET/MRI performs equally as well as currently used predictive tools to determine the risk for advanced disease.

12 Dec 2018

ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients

Innovation in immuno-oncology is exploding and new technologies that are set to benefit many patients with cancer are being showcased in the highly diverse array of topics to be discussed at the ESMO Immuno-Oncology Congress, to be held 13-16 December in Geneva, Switzerland.

11 Dec 2018

Lund University researchers succeed in obtaining dendritic cells by direct reprogramming

For the first time, a research team at Lund University in Sweden has successfully reprogrammed mouse and human skin cells into immune cells called dendritic cells.

9 Dec 2018

Men with inflammatory bowel disease have higher prostate cancer risk

Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.

7 Dec 2018

Acutely injured deceased-donor kidneys are suitable for transplant, study suggests

Organ procurement teams are sometimes leery of accepting kidneys from deceased donors with acute kidney injury, fearing they will harm the recipients. However, a national study chaired by a Johns Hopkins kidney specialist suggests these fears may be unfounded.

7 Dec 2018

UAB research may point a path to more effective influenza vaccines

Seasonal influenza vaccines are typically less than 50 percent effective, according to Centers for Disease Control and Prevention studies. Research at the University of Alabama at Birmingham, published this week in Nature Immunology, may point a path to more effective vaccines.

6 Dec 2018

New study confirms effectiveness of PSA screening in reducing prostate cancer deaths

A new study has confirmed the effectiveness of Prostate-specific Antigen screening in reducing prostate cancer mortality.

5 Dec 2018

From Our Bench to Yours: Antibody Advice from Proteintech

An interview with Dr. Karolina Szczesna, discussing the tell-tale signs of a good antibody and how Proteintech are working to improve experimental results for scientists.

From Proteintech Group, Inc 5 Dec 2018

Physician-scientists present updated efficacy data on CAR T-cell gene immunotherapy

Physician-scientists from Children's Hospital of Philadelphia presented updated efficacy and safety data on Kymriah--the first-ever U.S. Food and Drug Administration approved personalized CAR T-cell gene immunotherapy for aggressive blood cancers at the 60th American Society of Hematology annual meeting, as well as first-of-its-kind research on overcoming CAR T-cell resistance.

5 Dec 2018

Maryland researchers receive grant to study the brain-to-gut connection in schizophrenia

Researchers at the University of Maryland School of Medicine's Maryland Psychiatric Center and Institute for Genome Sciences, along with researchers at the University of Maryland School of Pharmacy, have been awarded a collaborative five-year $1.78 million grant to study the brain-to-gut connection in schizophrenia.

5 Dec 2018

Study: 39% of B cell lymphoma patients treated with CAR T therapy remain in remission

A new article published today in The Lancet Oncology shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy Yescarta remained in remission more than two years following therapy, and more than half of the patients treated remain alive.

4 Dec 2018

Scientists use genetically engineered immune cells to fight Hodgkin and non-Hodgkin lymphoma cells

University of North Carolina Lineberger Comprehensive Cancer Center researchers reported promising early results from a clinical study of an investigational cellular immunotherapy that used a patient's own, genetically engineered immune cells to recognize and fight Hodgkin and non-Hodgkin lymphoma cells.

4 Dec 2018

New strategies may improve performance of CAR-T cell therapy in treating cancer

Mayo Clinic researchers have developed two new strategies that may improve the performance of chimeric antigen receptor therapy in treating cancer. They are presenting results of their preclinical research at the 2018 annual meeting of the American Society of Hematology in San Diego.

3 Dec 2018

Study shows outcomes of CAR T-cell therapy when used as standard of care for lymphoma

Chimeric antigen receptor T-cell therapy, or CAR T, was named the 2017 Advance of the Year by the American Society of Clinical Oncology. The FDA approved two CAR T products last year for treatment of adult large B-cell lymphoma based on the exceptional patient outcomes seen in clinical trials.

3 Dec 2018

SSB enters into collaboration with Immunochina to develop new immunotherapy equipment

Sartorius Stedim Biotech, a leading international supplier of the biopharmaceutical industry, through its China affiliate, and Beijing-based Immunochina Pharmaceuticals, announced today that both parties have entered into a collaboration.

3 Dec 2018

Study: 51% of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma

A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma reported 51 percent of patients receiving an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel were still alive two years post-treatment.

3 Dec 2018

Antigen News and Research

Interval of time to biochemical failure could be used as surrogate endpoint for prostate cancer

FDA supports C-Path's Type 1 Diabetes Consortium to pursue biomarker qualification

Black men diagnosed with low-grade prostate cancer have higher risk of death, study shows

Surgical treatment unnecessary for many prostate cancer patients

Whole-body imaging PET/MRI offers information to guide treatment options for prostate cancer

ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients

Lund University researchers succeed in obtaining dendritic cells by direct reprogramming

Men with inflammatory bowel disease have higher prostate cancer risk

Acutely injured deceased-donor kidneys are suitable for transplant, study suggests

UAB research may point a path to more effective influenza vaccines

New study confirms effectiveness of PSA screening in reducing prostate cancer deaths

From Our Bench to Yours: Antibody Advice from Proteintech

Physician-scientists present updated efficacy data on CAR T-cell gene immunotherapy

Maryland researchers receive grant to study the brain-to-gut connection in schizophrenia

Study: 39% of B cell lymphoma patients treated with CAR T therapy remain in remission

Scientists use genetically engineered immune cells to fight Hodgkin and non-Hodgkin lymphoma cells

New strategies may improve performance of CAR-T cell therapy in treating cancer

Study shows outcomes of CAR T-cell therapy when used as standard of care for lymphoma

SSB enters into collaboration with Immunochina to develop new immunotherapy equipment

Study: 51% of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics